Jaundice, Neonatal, Neonatal Hyperbilirubinemia
Conditions
Keywords
Phototherapy, Blue light LED, Green Light LED
Brief summary
Phototherapy is the most frequently used treatment in neonatology when serum bilirubin levels exceed physiological limits. Light-emitting diodes (LEDs) are become routinely used for phototherapy in neonates with hyperbilirubinemia. Blue LED light with peak emission around 460 nm is regarded as the most suitable light sources for phototherapy and they recommended by most neonatal guidelines. However, the effectiveness of phototherapy with narrow-band LED light sources can be increased by expanding the spectral range of incident radiation within the absorption of bilirubin due to the strongly marked heterogeneity absorption properties of bilirubin in a different microenvironment. Longer wavelength light, such as green light, is expected to penetrate the infant's skin deeper. It is still controversial whether the use of green light has any advantage over blue light. The most effective and safest light source and the optimal method to evaluate phototherapy, however, remain unknown.The aim of this study was to compare, at equal light irradiance, the clinical efficacy of broad spectrum blue- green LED with blue narrow spectral band phototherapy device.
Interventions
DEVICEBlue-Green LED photoherapy
Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
Sponsors
Erebouni Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
no masking
Intervention model description
Prospective randomized controlled trial
Eligibility
Sex/Gender
ALL
Age
24 Hours to 14 Days
Healthy volunteers
No
Inclusion criteria
* non-haemolytic hyperbilirubinaemia, but otherwise healthy, indications for phototherapy based on NICE criteria, gestational age ≥33 weeks, birth weight ≥1800 g, postnatal age \>24 hrs and ≤14 days
Exclusion criteria
* hemolytic jaundice, major congenital animalities and history of phototherapy. Infants with indication of intensive treatment double phototherapy were not included.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bilirubin level reduction | 24 hours | Reduction in TSB levels after phototherapy for 24 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Days of phototherapy | Through study completion, an average of 1 month. | Duration of phototherapy |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse outcomes | Through study completion, an average of 1 month. | Any adverse effects or patologycal symptoms during phototherapy |
Countries
Armenia
Contacts
Primary ContactPavel Mazmanyan, Prof
Backup ContactGohar Margaryan, MD
Outcome results
None listed